Table:
text: Marine pharmacognosy
Compounds from Marine Sources in Clinical Level
Clinical Pipeline of Marine Pharmacology, July 2011. From http://marinepharmacology.midwestern.edu/clinPipeline.htm
Clinical_Status Compound_Name Trademark Marine_Organism_α Chemical_Class Molecular_Target Clinical_Trials_β Disease_Area
Phase III Plitidepsin Aplidin ® Tunicate Depsipeptide Rac1 and JNK Activation 1/7 Cancer
Phase II DMXBA (GTS-21) N/A Worm Alkaloid Alpha-7 Nicotinic Acetylcholine Receptor 0/3 Congnition , Schizophrenia
Phase II Plinabulin (NPI 2358) N/A Fungus Diketopiperazine Microtubules and JNK Stress Protein 1/2 Cancer
Phase II Elisidepsin Irvalec ® Mollusk Depsipeptide Plasma Membrane Fluidity 1/2 Cancer
Phase II PM00104 Zalypsis ® Nudibranch Alkaloid DNA-Binding 2/3 Cancer
Phase II Glembatumumab Vedotin (CDX-011) N/A Mollusk Antibody Drug Conjugate (MM Auristatin E) Glycoprotein NMB and Microtubules 1/3 Cancer
Phase I Marizomib (Salinosporamide A) N/A Bacterium Beta-Lactone-Gamma Lactam 20S Proteasome 4/4 Cancer
Phase I PM01183 N/A Tunicate Alkaloid Minor Groove of DNA N/A Cancer

Question: What is the molecular target listed under the Irvalec brand in marine pharmacognosy?

Question: What is the compound name where the marine organism α is a worm in marine pharmacognosy?

Question: How many compound names in marine pharmacognosy list a chemical class of depsipeptides and a β value for clinical trials of 1/7?

Question: What brand is listed for the molecular target: DNA binding in marine pharmacognosy?